Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 388
Topic area
  • Musculoskeletal

Provisional Schedule

Information meeting with consultees: 25 November 2003
Closing date for invited submissions / evidence submission: 03 February 2004
Final scope published: September 2003
1st appraisal committee meeting: 06 October 2004
2nd appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: West Midlands Health Technology Assessment Collaboration, University of Birmingham
Communications manager: Tonya Gillis
Executive Lead: Andrew Dillon
Project manager: Cathryn Fuller
Technical Lead: Elisabeth George and Sarah Garner

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
15 December 2004

This review has been suspended pending the outcome of the European Medicines Agency (EMEA) review of cox II inhibitors.

The clarifications requested by the Committee have now been completed, so that the Committee will have a final revised Assessment Report to consider when this topic is considered again. This meeting will be scheduled after the projected date for the issuing of the EMEA recommendations on cox II inhibitors.

In the meantime, the current NICE guidance (no. 27) on this health technology will continue to apply, with the caveat that rofecoxib has been withdrawn from sale by its manufacturers.


For further information on our processes and methods, please see our CHTE processes and methods manual